Hipertensi pada Kehamilan
DOI:
https://doi.org/10.30595/hmj.v2i2.4169Keywords:
pregnancy, hypertension, preeclampsia, antihypertensive drugsAbstract
Hipertensi pada kehamilan sering terjadi (6-10 %) dan meningkatkan risiko morbiditas dan mortalitas pada ibu, janin dan perinatal. Pre-eklampsia/eklampsia dan hipertensi berat pada kehamilan risikonya lebih besar. Hipertensi pada kehamilan dapat digolongkan menjadi pre-eklampsia/ eklampsia, hipertensi kronis pada kehamilan, hipertensi kronis disertai pre-eklampsia, dan hipertensi gestational. Pengobatan hipertensi pada kehamilan dengan menggunakan obat antihipertensi ternyata tidak mengurangi atau meningkatkan risiko kematian ibu, proteinuria, efek samping, operasi caesar, kematian neonatal, kelahiran prematur, atau bayi lahir kecil. Penelitian mengenai obat antihipertensi pada kehamilan masih sedikit. Obat yang direkomendasikan adalah labetalol, nifedipine dan methyldopa sebagai first line terapi. Penatalaksanaan hipertensi pada kehamilan memerlukan pendekatan multidisiplin dari dokter obsetri, internis, nefrologis dan anestesi. Hipertensi pada kehamilan memiliki tingkat kekambuhan yang tinggi pada kehamilan berikutnya. Hypertension complicates 6% to 10% of pregnancies and increases the risk of maternal, fetal and perinatal morbidity and mortality. Preeclampsia / eclampsia and severe hypertension in pregnancy are at greater risk. Four major hypertensive disorders in pregnancy have been described by the American College of Obstetricians and Gynecologists (ACOG): chronic hypertension; preeclampsia-eclampsia; chronic hypertension with superimposed preeclampsia; and gestational hypertension. The current review suggests that antihypertensive drug therapy does not reduce or increase the risk of maternal death, proteinuria, side effects, cesarean section, neonatal and birth death, preterm birth, or small for gestational age infants. The quality of evidence was low. Recommendations for treatment of hypertension in pregnancy are labetalol, nifedipine and methyldopa as first line drugs therapy. Although the obstetrician manages most cases of hypertension during pregnancy, the internist, cardiologist, or nephrologist may be consulted if hypertension precedes conception, if end organ damage is present, or when accelerated hypertension occurs. Women who have had preeclampsia are also at increased risk for hypertension in future pregnancies.
References
1. Bartsch, E., Medcalf, K.E., Park, A.L., et al., 2016. Clinical risk factors for pre-eclamsia determined in early pregnancy: systemic review and meta-analysis of large cohort studies. BMJ. Vol 353: i1753.
2. Bateman, B.T., Huybrechts, K.F., Maeda, A., et al., 2015. Calcium Channel Blocker Exposure in Late Pregnancy and the Risk of Neonatal Seizures. Obstetrics & Gynecology. Vol 126 (2): 271.
3. Bilano, V.L., Ota, E., Ganchimeg, T., et al., 2014. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a who secondary analysis. PLOS ONE. Vol 9 (3): e91198.
4. Brown, M.A., Magee, L.A., Kenny, L.C., et al., 2018. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertension. Vol 13: 291-310. https://doi.org/10.1016/j.preghy.2018.05.004.
5. Churchill, D., Beevers, G., Meher, S., et al., 2007. Diuretics for preventing pre‐eclampsia. Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD004451.pub2.
6. Cluver, C., Novikova, N., Koopmans, C.M., et al., 2017. Planned early delivery versus expectant management for hypertensive disorder from 34 weeks gestation to term. Cochrane Database of Systemic Review. Vol 1.
7. Collins, R., Yusuf, S., Peto, R., 1985. Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed). Vol 290 (6461): 17-23.
8. Coutts, J., 2007. Pregnancy-induced hypertension-the effects on the newborn; in Lyall, F. and Belfort, M., Pre-eclampsia: Etiology and Clinical Practice Ch. 33. Cambridge University Press. Cambridge.
9. Dahlof B, Devereux RB, Kjeldsen SE, et al., 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. Vol 359: 995-1003.
10. English, F.A., Kenny, L.C., and McCarthy, F.P., 2015. Risk factors and effective management of preeclampsia. Integrated Blood Pressure Control. Vol 8: 7-12.
11. Erwinanto, 2017. Definisi dan klasifikasi hipertensi in: Taruna, Y. and Widyantoro, B. Buku Ajar Hipertensi. Perhimpunan Dokter Hipertensi Indonesia. Jakarta.
12. Erwinanto, 2017. Klasifikasi hipertensi (primer dan sekunder) serta perjalanan penyakit in: Taruna, Y. and Widyantoro, B. Buku Ajar Hipertensi. Perhimpunan Dokter Hipertensi Indonesia. Jakarta.
13. Ferdinand, K., and Kountz, D.S., 2008. New Approaches to Managing Dyslipidemia: Risk Reduction Beyond LDL-C. Medscape. https://www.medscape.org/viewarticle/577753.
14. Hoeltzenbein, M., Beck., E., Fietz, A.K., et al., 2017. Pregnancy Outcome After First Trimester Use of Methyldopa. Hypertension. Vol 70 (1): 201-8.
15. Horvath JS, Phippard A, Korda A, Henderson-Smart DJ, Child A, Tiller DJ. Clonidine hydrochloride-a safe and effective antihypertensive agent in pregnancy. Obstet Gynecol. 1985; 66:634–8. https://doi.org/10.1016/0020-7292(87)90222-0.
16. Joesoef, A.H., dan Setianto, B., 2003. Hipertensi sekunder in: Rilantono dkk (ed). Buku Ajar Kardiologi. FKUI. Jakarta.
17. Kaplan, N.M. and Rose, D., 2010. Prehypertension and borderline hypertension. http://www.uptodate.com/store.
18. Kaplan, N.M., 2015. Primary hypertension: pathogenesis in: Kaplan, N., Rose, B., Bakris, G.L., Sheridan, A.M., Kaplan’s Clinical Hypertension, 11th ed Linppincol William & Willkins Phylladephia. Pp: 50-121.
19. Kario, 2018. Central Sympathetic Agents and Direct Vasodilators in Hypertension: A Companion to Braunwald's Heart Disease (Third Edition) Ch 26. Elsevier.
20. Karthikeyan, V.J., 2015. Hypertension in pregnancy; in Nadar, S. and Lip, G.Y.H., Hypertension, Ch. 22, 2nd Ed. Oxford Cardiology Library. Oxford.
21. Kementerian Kesehatan Republik Indonesia., 2018. Profil Kesehatan Indonesia Tahun 2017. Kemenkes RI.
22. Kementerian Kesehatan Republik Indonesia., 2017. Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/659/2017 Tentang Formularium Nasional. Diberlakukan Tahun 2018. Kemenkes RI.
23. Khan, K., Zamora, J., Lamont, R.F., et al., 2010. Safety concerns for the use of calcium channel blockers in pregnancy for the treatment of spontaneous preterm labour and hypertension: a systematic review and meta-regression analysis. The Journal of Maternal-Fetal & Neonatal Medicine. Vol 23 (9): 1030-8.
24. Khosravi, S., Dabiran, S., Lotfi, M., et al., 2014. Study of the prevalence of hypertension and complications of hypertensive disorders in pregnancy. Open Journal of Preventive Medicine. Vol 4: 860-7.
25. Leeman, L., Dresang, L.T., and Fontaine, P., 2016. Hypertensive disorder of pregnancy. American Family Physicians. Vol 93 (2): 121-7.
26. Leslie, D. and Collins, R.E., 2016. Hypertension in pregnancy. BJA Education. Vol 16 (1): 33-7. https://doi.org/10.1093/bjaceaccp/mkv020.
27. Lovell, A.R., and Ernst, M.E., 2017. Drug-Induced Hypertension: Focus on Mechanisms and Management. Curr Hypertens Rep. Vol 19 (5): 39.
28. Lowe, S.A., Bowyer, L., Lust, K., et al., 2014. The SOMANZ guideline for the management of hypertensive disorders of pregnancy. SOMANZ.
29. Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, Asztalos E, Murphy KE, Menzies J, Sanchez J, Gafni A, Gruslin A, Helewa M, Hutton E, Koren G, Lee SK, Logan AG, Ganzevoort JW, Welch R, Thornton JG, Moutquin J-M. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG 2016;123:1143–1151.
30. Malha, L., Podymow, T., August, P., et al., 2018. Hypertension in Pregnancy in Hypertension: A Companion to Braunwald's Heart Disease (Third Edition) Ch 39. Elsevier.
31. Matthews, G., Gornall., R., Saunders, N., 1997. A randomised placebo controlled trial of loop diuretics in moderate/severe pre-eclampsia, following delivery. Journal of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and Gynaecology. Vol 17 (1): 30-2. https://doi.org/10.1080/01443619750114040.
32. Mudjari, N.S., and Samsu, N., 2015. Management of hypertension in pregnancy. Acta Med Indones-Indones J Intern Med. Vol 47 (1): 78-86.
33. Mustafa, R., Ahmed, S., Gupta, A., et al., 2012. A comprehensive review of hypertension in pregnancy. Journal of Pregnancy. Vol 2012.
34. Nadar, S., 2015. Pathophysiology of hypertension in Oxford Cardiology Library Hypertension 2nd Edition Ch 2. Oxford University Press.
35. National Institute for Health and Clinical Excellence (NICE), 2011. Hypertension in pregnancy: the management of hypertensive disorder during pregnancy. Royal College of Obstetricians and Gynaecologists. London.
36. O'Donnell, A., McParlin, C., Robson, Sc., et al., 2016. Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review and economic assessment. Health Technology Assessment. Vol 20 (74).
37. Ogura et al., 2019. Antihypertensive drug therapy for women with non-severe hypertensive disorders of pregnancy: a systematic review and meta-analysis. Hypertension Research. https://doi.org/10.1038/s41440-018-0188-0.
38. Olson-Chen, C., and Seligman, N.S., 2016. Hypertensive Emergencies in Pregnancy. Critical Care Clinics. Vol 32 (1): 29-41. https://doi.org/10.1016/j.ccc.2015.08.006.
39. Patel, P., Koli, D., Maitra, N., et al., 2018. Comparison of Efficacy and Safety of Intravenous Labetalol Versus Hydralazine for Management of Severe Hypertension in Pregnancy. J Obstet Gynaecol India. Vol 68 (5): 376-81. https://doi.org/10.1007/s13224-017-1053-9.
40. Regitz-Zagrosek, V., 2018. ‘Ten Commandments’ of the 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. Vol 39 (35): 3269. https://doi.org/10.1093/eurheartj/ehy478
41. Roberts, J.M., August, P.A., Bakris, G., et al., 2013. Hypertension in Pregnancy. American College of Obstetricians and Gynecologist. Washington DC.
42. Rothenberger, S., Carr, D., Brateng, D., et al., 2010. Pharmacodynamics of Clonidine Therapy in Pregnancy: a Heterogeneous Maternal Response Impacts Fetal Growth. American journal of hypertension. Vol 23 (11): 1234-40. https://doi.org/10.1038/ajh.2010.159.
43. Seely, E.W., and Ecker, J., 2014. Chronic hypertension in pregnancy. Circulation. Vol 129: 1254-61.
44. Sharma, C., Soni, A., Gupta, A., 2017. Hydralazine vs nifedipine for acute hypertensive emergency in pregnancy: a randomized controlled trial. American Journal of Obstetrics & Gynecology. Vol 217 (6): 687.e1-687.e6. https://doi.org/10.1016/j.ajog.2017.08.018.
45. Sibai, B.M., and Chames, M.C., 2008. Chronic hypertension in pregnancy. Glob. Libr. Women's Med. http://www.glowm.com/index.html?p=glowm.cml/section_view&articleid=156.
46. Siregar, T.G.M., 2003. Hipertensi esensial in: Rilantono dkk (ed). Buku Ajar Kardiologi. FKUI. Jakarta.
47. Suhardjono, 2017. Hipertensi sekunder in: Taruna, Y. and Widyantoro, B. Buku Ajar Hipertensi. Perhimpunan Dokter Hipertensi Indonesia. Jakarta.
48. Sutters, M., 2017. Systemic hypertension, in McPhee, S., Papadakis, M.A.(eds). Current Medical Diagnosis and Treatment. McGrawHill Lange. New York. P: 439-71.
49. Tranquilli, A.L., Dekker, G., Magee, L., et al., 2014. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the isshp. Pregnancy Hypertension: An international Journal of Women’s Cardiovaskular Health. Vol 4 (2): 97-104.
50. Vidal S.M., Schneck, M.J., Flaster, M.S., et al., 2011. Stroke- and pregnancy-induced hypertensive sindromes. Women’s Health. Vol 7 (3): 283-92.
51. Ward, K. and Lindheimer, M.D., 2009. Genetic factors in the etiology of pre-eklampsia/eklampsia in: Taylor, R.N., Robert, J.M., Cunningham, F.G., et al., Chesley’s Hypertensive Disorder in Pregnancy Ch. 4, 4th ed. Elsevier Inc. Cambridge.
52. Webster, L.M., Myers, J.E., Nelson-Piercy, C., et al., 2017. Labetalol Versus Nifedipine as Antihypertensive Treatment for Chronic Hypertension in Pregnancy. Hypertension. Vol 70 (5): 915-22. https://doi.org/10.1161/HYPERTENSIONAHA.117.09972.
53. Whelton, P.K., Carey, R.M., Aronow, W.S., Casey, D.E., et al., 2017. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017. https://doi.org/10.1161/HYP.0000000000000065.
54. Whelton P.K., Appel L.J., Espeland M.A., et al., 1998. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. Vol 279: 839-46.
55. Whelton P.K., 2015. The elusiveness of population-wide high blood pressure control. Annu Rev Public Health. Vol 36:109-30.
56. Wiener, C., Kasper, D.L., Fauci, A.S., et al., 2017. Harrison's Principles of Internal Medicine Self-Assessment and Board Review, 19th Edition. McGraw-Hill Education/Medical. ISBN 978-1-259-64288-3.
57. Williams, B., Mancia, G., Spiering, W., et al., 2018. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. Vol 39 (33): 3021-104. https://doi.org/10.1093/eurheartj/ehy339.
58. World Health Organization (WHO), 2013. A Global Brief on Hypertension. World Health Day 2013.
Downloads
Published
How to Cite
Issue
Section
License
For submission of manuscripts to the Herb-Medicine Journal, the authors must certify that:
I have been authorized by my co-author to submit the manuscript to the Herb-Medicine Journal
I hereby declare, on behalf of myself and my co-authors, that:
The submitted manuscript is original work and has not been published in another peer-reviewed journal or is being considered for publication by another journal. Also, the manuscript does not infringe any existing copyright or other third party rights.
The manuscript does not contain material that may violate the law, slander, or SARA, in any way, violates the terms and conditions contained in the agreement
I/we have taken care that the scientific knowledge and all other statements contained in the manuscript are in accordance with authentic facts and formulas and will not, if followed appropriately, harm the user
No liability shall be assumed by Herb-Medicine Journal, its staff or members of the editorial board for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from the use or operation of any method, product instructions, advertising , or ideas contained in publications by the Herb-Medicine Journal
Authors who publish in the Herb-Medicine Journal certify that all authors have read and agree to the contents of the Cover Letter or the Terms and Conditions. Plagiarism is strictly prohibited, and by submitting a manuscript for publication, the author agrees that the publisher has the legal right to take appropriate action against the author, if plagiarism or false information is found. Once submitted to the Herb-Medicine Journal, authors will not withdraw their manuscript at any stage prior to publication.
The author owns the copyright and grants the journal rights for first publication with the work simultaneously licensed under a Creative Commons Attribution License which allows others to share the work with acknowledgment of the work's authorship and initial publication in this journal.
Authors may enter into separate additional contractual agreements for the non-exclusive distribution of the published journal version of the work (for example, posting it to an institutional repository or publishing it in a book), with acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their websites) prior to and during the submission process, as this can lead to productive exchanges, as well as earlier and larger citation of published work (See The Effects of Open Access).
Untuk pengiriman naskah ke Herb-Medicine Journal, penulis harus menyatakan bahwa:
- Saya telah diberikan otorisasi oleh rekan penulis saya untuk memasukkan naskah ke Herb-Medicine Journal
- Saya dengan ini menyatakan, atas nama saya dan rekan penulis saya, bahwa:
- Naskah yang dikirimkan adalah karya asli dan belum pernah diterbitkan dalam jurnal peer-review lain atau sedang dipertimbangkan untuk diterbitkan oleh jurnal lain. Serta, naskah tidak melanggar hak cipta yang ada atau hak pihak ketiga lainnya.
- Naskah tidak mengandung materi yang mungkin melanggar hukum, memfitnah, atau SARA, dengan cara apa pun, melanggar syarat dan ketentuan yang tercantum dalam perjanjian
- Saya / kami telah berhati-hati bahwa pengetahuan ilmiah dan semua pernyataan lain yang terkandung dalam naskah sesuai dengan fakta dan formula otentik dan tidak akan, jika diikuti dengan tepat, merugikan pengguna
- Tidak ada tanggung jawab yang ditanggung oleh Herb-Medicine Journal, stafnya atau anggota dewan editorial untuk setiap cedera dan/atau kerusakan pada orang atau properti sebagai masalah pertanggungjawaban produk, kelalaian atau sebaliknya, atau dari penggunaan atau pengoperasian metode, produk apa pun instruksi, iklan, atau ide yang terkandung dalam publikasi oleh Herb-Medicine Journal
Penulis yang menerbitkan dalam Herb-Medicine Journal menyatakan bahwa semua penulis telah membaca dan menyetujui isi Surat Pengantar atau Syarat dan Ketentuan. Plagiarisme dilarang keras, dan dengan menyerahkan naskah untuk publikasi, penulis setuju bahwa penerbit memiliki hak hukum untuk mengambil tindakan yang pantas terhadap penulis, jika ditemukan plagiarisme atau informasi palsu. Setelah diserahkan ke Herb-Medicine Journal, penulis tidak akan menarik naskah mereka pada tahap apa pun sebelum dipublikasikan.
Penulis memiliki hak cipta dan memberikan hak jurnal untuk publikasi pertama dengan karya yang secara simultan dilisensikan di bawah Lisensi Creative Commons Attribution yang memungkinkan orang lain untuk berbagi karya dengan pengakuan kepengarangan karya dan publikasi awal dalam jurnal ini.
Penulis dapat membuat perjanjian kontrak tambahan yang terpisah untuk distribusi non-eksklusif versi jurnal yang diterbitkan dari karya tersebut (misalnya, mempostingnya ke repositori institusional atau menerbitkannya dalam sebuah buku), dengan pengakuan atas publikasi awalnya di jurnal ini.
Penulis diizinkan dan didorong untuk memposting pekerjaan mereka secara online (misalnya, dalam repositori institusional atau di situs web mereka) sebelum dan selama proses pengajuan, karena dapat menyebabkan pertukaran yang produktif, serta kutipan yang lebih awal dan lebih besar dari karya yang diterbitkan (Lihat The Effect of Open Access).
